The Filing Desk

Clene

CLNN · Nasdaq · Health Care · Financials, fiscal 2019 to 2025

CLNN · Last close · November 19, 2026
$3.50
Value Clene yourself

Clene's revenue fell 41.5% to $0 million in fiscal 2025. Its operating margin was −11,541.5%, down from −9,676.3% a year earlier. Free cash flow was −$19 million. The diluted share count rose 41.8%.

Clene Inc. Latest fiscal year ended December 31, 2025 10-K filed March 17, 2026 · 0001437749-26-008502 Updated
Revenue
$0M
41.5%
Operating margin
−11,541.5%
1865.2 pts
Net income
−$26M
 
Free cash flow
−$19M
 
Return on equity
—
 
Market cap
$51M
Nov 19 close
P/E
—
 

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (1-for-20), so every year is on today's share basis. Return on equity for fiscal 2025 is blank: the 10-K's structured data doesn't include current portion of long-term debt.

Charts show fiscal years, from the 10-K filings.

What Clene does

Clene is a drug developer that has no approved medicine yet; in industry terms, it is clinical-stage. It makes tiny crystals of metals, such as gold, suspended in water, which it calls clean-surfaced nanotechnology (CSN) therapeutics. The company says these crystals help stressed or damaged cells make and use energy, and it is testing them in diseases of the brain and nervous system.

Its main drug candidate, CNM-Au8, is a liquid of gold nanocrystals that patients drink. Clene is studying it in amyotrophic lateral sclerosis (ALS, a fatal disease that destroys the nerves controlling muscles), multiple sclerosis (MS) and Parkinson's disease. Several trials have finished, and it still runs programs that give the drug to ALS patients who cannot join trials. It has discussed with the U.S. Food and Drug Administration whether it could apply for faster, accelerated approval in ALS; the FDA's neurology division at one point said Clene's material did not support such an application.

Clene does not sell any drug. Its small revenue comes from low-dose versions of its products sold as dietary supplements, mainly through a license and supply deal with 4Life, a supplement seller that is also a Clene shareholder and lender. Clene makes its drug candidates itself, at plants in Maryland, and had 79 employees at the end of 2025, mostly in Utah and Maryland.

Its biggest risks, as it describes them

  • It has no approved drug and its future depends on CNM-Au8, which regulators may not approve or may approve only after long delays.
  • It has lost money since it began and needs more funding to keep operating, which may not be available.
  • Earlier trial results may not hold up in later trials, and slow patient enrollment could delay its studies.
  • It makes all its drug candidates itself, so problems or damage at its own plants could halt supply.
  • Even if approved, its drugs may not win acceptance from doctors, patients and insurers, or fair pricing.
From Clene's annual report on Form 10-K, filed March 17, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Clene lost money in fiscal 2025: a net loss of $26 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments502335125
Debt incl. finance leases151616518
Net debt (negative means net cash)−36−7−18−713
Net debt to EBITDA—————
Debt to equity1.2x5.0x1.2x——
Interest coverage−57.5x−14.7x−8.9x−8.1x−8.6x
Current ratio9.1x2.1x1.5x1.6x0.8x
Quick ratio9.1x2.1x1.5x1.6x0.8x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Clene's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $250,904 of Clene shares on the open market, and 1 insider sold $5.8 million.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 18, 2026Reed N WilcoxDirectorBought10,000$3.42$34,240Form 4
May 12, 2026Chidozie Ugwumba10% ownerSold73,296$6.20$454,435Form 4
May 11, 2026Chidozie Ugwumba10% ownerSold22,177$6.75$149,695Form 4
May 4, 2026Chidozie Ugwumba10% ownerSold72,884$6.80$495,611Form 4
May 1, 2026Chidozie Ugwumba10% ownerSold5,795$6.01$34,828Form 4
Apr 30, 2026Chidozie Ugwumba10% ownerSold5,736$6.08$34,875Form 4
Apr 29, 2026Chidozie Ugwumba10% ownerSold12,170$5.63$68,517Form 4
Apr 28, 2026Chidozie Ugwumba10% ownerSold1,591$5.90$9,387Form 4
Apr 21, 2026Chidozie Ugwumba10% ownerSold61,345$6.14$376,658Form 4
Apr 20, 2026Chidozie Ugwumba10% ownerSold4,318$6.12$26,426Form 4
Apr 17, 2026Chidozie Ugwumba10% ownerSold25,040$6.43$161,007Form 4
Apr 16, 2026Chidozie Ugwumba10% ownerSold7,748$6.40$49,587Form 4
The latest 12 of 64 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score2 of 94 of 92 of 9
Rule of 40−4,625.5%−6,287.8%−9,334.0%
Altman Z''−18.27−40.63−65.16
Accruals ratio−39.9%−45.4%−33.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassFail
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin roseFailFailFail
Revenue rose relative to assetsPassFailPass
F-score2 of 94 of 92 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Clene side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
CleneFY25−41.5%−11,541.5%−9,292.5%——2
Lisata TherapeuticsFY25−83.0%−10,711.2%−9,398.2%——1Compare
ABVC BioPharmaFY25−41.9%−2,416.0%————Compare
Allarity TherapeuticsFY25—−3,939.1%−4,633.8%———Compare
Actinium PharmaceuticalsFY25—−40,274.4%−27,426.7%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue—010100
Revenue growth——251.0%−34.6%38.3%−47.7%−41.5%
Gross profit——00000
Research and development10152832272014
Operating income−16−20−50−48−40−33−23
Net income−16−19−10−30−50−39−26
Diluted EPS (US$)−18.60−22.00−3.20————
Diluted shares (millions)11335710
Cash flow
Cash from operations−13−19−35−39−30−21−18
Capital expenditure0015000
Free cash flow−13−19−36−44−30−21−19
Dividends paid0000000
Share buybacks0000000
Acquisitions0000000
Stock-based compensation01128986
Balance sheet at fiscal year end
Cash and short-term investments959502335125
Debt incl. finance leases18151616518
Total assets15686344522718
Total liabilities10685041393636
Shareholders' equity−68013313−9−18
Margins and ratios
Gross margin——60.0%94.5%81.5%79.5%78.5%
Operating margin—−9,812.6%−6,912.6%−10,234.5%−6,198.8%−9,676.3%−11,541.5%
Net margin—−9,357.8%−1,347.2%−6,325.2%−7,569.4%−11,520.5%−13,086.5%
Free cash flow margin—−9,376.7%−4,973.2%−9,342.5%−4,663.8%−6,240.1%−9,292.5%
Rule of 40 (growth + FCF margin)——−4,722.2%−9,377.1%−4,625.5%−6,287.8%−9,334.0%
Return on capital———————
Return on equity——−150.6%−377.9%−595.5%−1,738.4%—
Return on assets—−46.4%−14.8%−55.6%−102.2%−98.9%−115.1%
Net debt to EBITDA———————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Clene's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Clene.